UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037106
Receipt number R000041679
Scientific Title Clinical study of GLP-1 receptor agonist (Exenatide) for type 2 diabetes patients with diabetic nephropathy
Date of disclosure of the study information 2019/06/19
Last modified on 2019/06/19 10:13:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical study of GLP-1 receptor agonist (Exenatide) for type 2 diabetes patients with diabetic nephropathy

Acronym

Clinical study of exenatide for type 2 diabetes patients with diabetic nephropathy

Scientific Title

Clinical study of GLP-1 receptor agonist (Exenatide) for type 2 diabetes patients with diabetic nephropathy

Scientific Title:Acronym

Clinical study of exenatide for type 2 diabetes patients with diabetic nephropathy

Region

Japan


Condition

Condition

type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Accumulated cases where single administration of a GLP-1 agonist was administered to type 2 diabetes patients with inadequate glycemic control with diabetic nephropathy, or accumulated cases where the sulfonylurea drug ,thiazolidine drug, biguanide drug, a-glucosidase inhibitor, glinide drug were coadministered, GLP-1 action to investigate the efficacy and safety of the drug's hypoglycemic action and its effect on renal function.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Rate of change of delta eGFR at 12 weeks before and after administration

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administer GLP-1 receptor agonist (Exenatide)

1. In principle, this drug is administered within 60 minutes before morning supper and not after meals.
2. The administration of this drug starts with 5 ug once a day, twice a day. After increasing the dose from 5 ug to 10 ug, hypoglycemia and gastrointestinal disorders tend to increase. Therefore, at least one month after the start of administration, follow-up, and in consideration of efficacy and safety, Carefully judge whether to increase the amount to 10 ug at once or twice a day.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

Patients with type 2 diabetes who meet the criteria below
1) HbA1c (NGSP): 7.0% or more and less than 10%
2) Patients aged 20 years or older and less than 80 years regardless of gender
3) Diabetic nephropathy stage 2-3 (diagnostic criteria attached)
4) Patients who can obtain written consent to participate in this clinical research

Key exclusion criteria

Patients who fall under any of the following are excluded from this clinical study.
1) Patients who fall under the contraindication for GLP-1 receptor agonist
2) Patients participating in other clinical research
3) Pregnant women, pregnant women, lactating women or women who may have pregnancy
4) Patients with other serious complications
5) Patients judged to be unsuitable as a target by the judgment of other doctors

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Koji
Middle name
Last name Murao

Organization

Kagawa University Hospital

Division name

Department of Endocrinology and Metabolism

Zip code

761-0793

Address

Ikenobe 1750-1, Miki-cho, Kita-gun, Kagawa

TEL

0878985111

Email

labmed@med.kagawa-u.ac.jp


Public contact

Name of contact person

1st name Kensaku
Middle name
Last name Fukunaga

Organization

Kagawa University Hospital

Division name

Department of Endocrinology and Metabolism

Zip code

761-0793

Address

Ikenobe 1750-1, Miki-cho, Kita-gun, Kagawa

TEL

0878985111

Homepage URL


Email

labmed@med.kagawa-u.ac.jp


Sponsor or person

Institute

Kagawa University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kagawa University of Medicine Ethics Committee

Address

Ikenobe 1750-1, Miki-cho, Kita-gun, Kagawa

Tel

0878985111

Email

chiken@med.kagawa-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 06 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2015 Year 11 Month 01 Day

Date of IRB

2015 Year 11 Month 01 Day

Anticipated trial start date

2015 Year 12 Month 01 Day

Last follow-up date

2020 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 06 Month 19 Day

Last modified on

2019 Year 06 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041679


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name